References
- Kurono Y, Fujiyoshi T, Mogi G. Secretory IgA and bacterial adherence to nasal mucosal cells. Ann Otol Rhino Laryngol 1989; 98: 273–7
- Abu-Ghazaleh R I, Fujisawa T, Mestecky J, Kyle R A, Gleich GJ. IgA-induced eosinophil degranulation. J Immunol 1989; 142: 2393–400
- Fujisawa T, Abu-Gazaleh R, Kita H, Sanderson C J, Gleich GJ. Regulatory effect of cytokines on eosinophil degranulation. J Immunol 1990; 144: 642–6
- Venge P, Roxin L E, Olsson I. Radioimmunoassay of human eosinophil cationic protein. Br J Haematol 1977; 37: 331–5
- Fujita S. Determination of serum immunoglobulins and a-fetoprotein by latex agglutination photometric immunoassay. Jpn J Clin Lab Auto 1983; 8: 57–61
- Takahashi T. A study on measurement of the IgA, the secretion-type, in human saliva, using the enzyme immunoassay (EIA) method. Nihon Univ Dent J 1984; 58: 627–35, in Japanese
- Terada N, Konno A, Tada H, Shirotori K, Ishikawa K, Togawa K. The effect of recombinant interleukin-5 on eosinophil accumulation and degranuration in human nasal mucosa. J Allergy Clin Immunol 1992; 90: 160–8
- Terada N, Konno A, Togawa K. Biochemical properties of eosinophils and mechanism of their preferential accumulation in nasal allergy. J Allergy Clin Immunol 1994; 94: 629–42
- Dahl R, Fredens K, Marcussen C, Venge P. Eosinophils and bronchial injury. Annual Meeting of European Academy of Allergology and Clinical Immunology 1985; 63976, Abstr
- Frigas R, Loegering D A, Gleich GJ. Cytotoxic effects of the guinea pig eosinophil major basic protein in tracheal epithelium. Lab Invest 1990; 42: 35–43
- Konno A, Terada N, Ito E, Okamoto Y, Togawa K. The reaction of the nasal mucosa to platelet activating factor and leukotriens in nasal allergy. ORL Tokyo 1988; 31: 241–2, Suppl 7
- Terada N, Konno A, Fukuda S, et al. Interleukin-5 gene expression in nasal mucosa and changes in amount of interleukin-5 in nasal lavage after antigen challenge. Acta Otolaryngol (Stockh) 1994; 114: 203–8
- Sanderson C, Warren D, Strath M. Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to IL3, and functional properties of eosinophil differentiation in cultures. J Exp Med 1985; 162: 60–6
- Clutterbuck E J, Hurst E MA, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6 and GMCSF. Blood 1989; 73: 1504–12
- Harriman G R, Kunimoto D Y, Elliott J F, Paetkau V, Strober W. The role of IL-5 in IgA B cell differentiation. J Immunol 1988; 140: 3033–9
- Beagley K W, Eldridge J H, Kiyono H, Everson P, Koopman WJ. Recombinant IL-5 induced high rate synthesis in cycling IgA-positive Payer's patch B cells. J Immunol 1989; 141: 2035–42
- Lopez A F, Sanderson C J, Gamble J R, Campbell H D, Young I G, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167: 219–24
- Rothenberg M E, Peterson J, Stevens R L, et al. IL-5 dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability: accelerated hypoden-sity and sustained antibody-dependent cytotoxicity. J Immunol 1989; 143: 2311–6